Popular weight-loss drug Wegovy could be made available under more health insurance schemes following the results of a late-stage trial, analysts said Wednesday. Novo Nordisk’s closely watched “SELECT” trial exceeded expectations Tuesday, indicating that Wegovy reduced the risk of major cardiovascular events such as heart attacks or strokes by 20%. “Data like this is going … Read more
A split Food and Drug Administration decision on a new depression medicine from Sage Therapeutics and Biogen blew holes in the strategies of both companies and raised questions about the future of their collaboration. Late on Friday, the FDA approved a two-week course of the pill Zurzuvae as a treatment for postpartum depression, but not … Read more
The market is buzzing with demand for obesity pills, but Allurion Technologies is building a case that its weight loss platform—a medical device and software—is a worthy competitor to these drugs and perhaps even a companion to them. The company made debuted on the stock market debut Wednesday, raising $100 million to support commercialization of … Read more
Hospitals, and especially nonprofit hospitals, have a duty of care to their communities, but their ability to provide that care hinges on their ability to generate revenue – chiefly in the form of patient and insurer payments. But that model is growing more difficult as the commercially insured population ages into Medicare and those with employer-sponsored … Read more
The $76 Billion Diet Industry Asks: What to Do About Ozempic? The Wall Street Journal Source link